Experience in using Aterixen® in clinical practice. Results of the "SUPRA" observation program

Background. The new medical product Aterixen® (XC221GI) has appeared on the pharmaceutical market in 2022. It was revealed, at preclinical stage, that the main anti-inflammatory drug's effect was assured by its effect on production of anti-inflammatory cytokines IL-6, IL-8 and chemokines IP-10 (CXCL10), MIG (CXCL9). The results of double-blind randomized placebo-controlled studies have shown high efficacy of the drug in the management of patients with new coronavirus infection (COVID-19) of different severity.

Aim. To evaluate experience of Atherixen® practical use among physicians and general practitioners.

Materials and methods. The observational program included patients aged from 18 to 60 years with confirmed diagnosis of mild COVID-19. All patients have signed voluntary informed consent to participate in the study. The study consisted of 2 periods: screening period and drug administration period. All patients received Aterixen® (100 mg tablets), 1 tablet 2 times per day for 14 days within the standard therapy outlined in the Temporary methodological recommendations on prevention, diagnosis, and treatment of COVID-19. Efficacy was assessed by mean disease duration and physician and patient treatment satisfaction via five-point Likert scale.

Results. The average disease duration did not exceed 9.5 days. It indicates the ability of Aterixen® to prevent the transition of the disease to moderate and severe forms. The degree of physician and patient treatment satisfaction via five-point Likert scale in the vast majority of cases corresponded to the highest grades. Moreover, no adverse events were reported during the study and all patients had high tolerability.